Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANE
Phase 1
- Conditions
- stage II melanomaTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method